# Bitopertin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bitopertin

> Bitopertin, sponsored by Disc Medicine, Inc. (IRON), received a complete response letter from the FDA; the decision is dated February 13, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is bitopertin FDA approved?

Not as of November 16, 2026. Bitopertin, sponsored by Disc Medicine, Inc. (IRON), received a complete response letter from the FDA; the decision is dated February 13, 2026. SEC Form 8-K: "On February 13, 2026, Disc Medicine, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the New Drug Application ("NDA") for bitopertin as a treatment for patients with erythropoietic protoporphyria ("EPP")." [Calendar and source filings](https://sec-api.dev/pdufa/bitopertin)

Source: SEC Form 8-K, accession 0001193125-26-051504, https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/bitopertin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | bitopertin |
| Codes | DISC-1459, RO4917838 |
| Sponsor | Disc Medicine, Inc. (IRON) https://sec-api.dev/companies/iron/catalysts |
| Indications | [erythropoietic protoporphyria](https://sec-api.dev/indications/erythropoietic-protoporphyria), Erythropoietic Protoporphyria (EPP) |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### Apr 2022: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-11-12, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001193125-25-268200): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA, and we initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-268200): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA and initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm
- SEC Form 10-Q (accession 0001816736-25-000007): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA, and we initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000181673625000007/iron-20250630.htm
- SEC Form 10-Q (accession 0001816736-25-000007): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA and initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000181673625000007/iron-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065069): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA, and we initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm
- SEC Form 10-Q (accession 0000950170-25-065069): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA and initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm
- SEC Form 10-K (accession 0000950170-25-028390): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA, and we initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA and initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-124650): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA, and we initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000095017024124650/iron-20240930.htm
- SEC Form 10-Q (accession 0000950170-24-124650): "For example, we filed an IND in April 2022 with the FDA to initiate the AURORA Phase 2 trial of bitopertin in EPP patients, but the FDA initially placed the initiation of this trial on clinical hold; we received clearance to initiate the study in July 2022 after the study design was finalized with the FDA and initiated the study in October 2022." https://www.sec.gov/Archives/edgar/data/1816736/000095017024124650/iron-20240930.htm

### Sep 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-02-27, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448729): "In September 2025 we submitted a New Drug Application, or NDA, for accelerated approval of bitopertin in EPP and XLP in the United States based on our Phase 2 data." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "For example, we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States in September 2025." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "In September 2025, we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States and we requested a rare pediatric disease review voucher." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-450184): "In September 2025 we submitted a New Drug Application, or NDA, for accelerated approval of bitopertin in EPP and XLP in the United States based on our Phase 2 data." https://www.sec.gov/Archives/edgar/data/1816736/000119312526450184/d187305d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-427982): "In September 2025 we submitted a New Drug Application, or NDA, for accelerated approval of bitopertin in EPP and XLP in the United States based on our Phase 2 data." https://www.sec.gov/Archives/edgar/data/1816736/000119312526427982/d190758d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-425425): "In September 2025 we submitted a New Drug Application, or NDA, for accelerated approval of bitopertin in EPP and XLP in the United States based on our Phase 2 data." https://www.sec.gov/Archives/edgar/data/1816736/000119312526425425/d190758d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "In September 2025 we submitted a New Drug Application, or NDA, for accelerated approval of bitopertin in EPP and XLP in the United States based on our Phase 2 data." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "For example, we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States in September 2025." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "In September 2025, we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States and we requested a rare pediatric disease review voucher." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "For example, we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States in September 2025." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "In September 2025, we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States and we requested a rare pediatric disease review voucher." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073602): "In September 2025 we submitted an NDA for accelerated approval of bitopertin in EPP and XLP in the United States based on our existing data." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm

### Nov 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2026-02-26, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448729): "The U.S. Food and Drug Administration, or the FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-450184): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526450184/d187305d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-427982): "The U.S. Food and Drug Administration, or FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526427982/d190758d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-425425): "The U.S. Food and Drug Administration, or FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526425425/d190758d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073602): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073602): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm

### Nov 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-02-26, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448729): "The U.S. Food and Drug Administration, or the FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-450184): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526450184/d187305d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-427982): "The U.S. Food and Drug Administration, or FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526427982/d190758d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-425425): "The U.S. Food and Drug Administration, or FDA, accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526425425/d190758d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073602): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a complete response letter, or CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073602): "The FDA accepted our NDA for review in November 2025 and in February 2026 issued a CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm

### February 13, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: erythropoietic protoporphyria.
- First seen 2026-02-13, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448729): "For example, in February 2026, the FDA issued a CRL in response to our NDA for accelerated approval of bitopertin for EPP and XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "For example, in February 2026, the FDA issued a CRL in response to our NDA for accelerated approval of bitopertin for EPP and XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "For example, in February 2026, the FDA issued a CRL in response to our NDA for accelerated approval of bitopertin for EPP and XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 8-K (accession 0001193125-26-051504): "On February 13, 2026, Disc Medicine, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the New Drug Application ("NDA") for bitopertin as a treatment for patients with erythropoietic protoporphyria ("EPP")." https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm
- SEC Form 8-K (accession 0001193125-26-051504): "On February 13, 2026, the Company received a CRL from the FDA for the Company's NDA for bitopertin as a treatment for patients with EPP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-051504): "(February 13, 2026) - Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced that the U.S. Food and Drug Administration (FDA) today issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for bitopertin as a treatment for patients with erythropoietic protoporphyria (EPP)." https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "In February 2026, the FDA issued a CRL indicating that, while accelerated approval was not warranted, results from an additional clinical trial, such as our APOLLO clinical trial, could serve as evidence to support a potential traditional approval." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "In February 2026, the FDA issued a CRL indicating that, while accelerated approval was not warranted, results from an additional clinical trial, such as our ongoing APOLLO clinical trial, could serve as evidence to support a potential traditional approval." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "In February 2026, the FDA issued a CRL indicating that, while accelerated approval was not warranted, results from an additional clinical trial, such as our ongoing APOLLO clinical trial, could serve as evidence to support a potential traditional approval." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "However, receipt of the CNPV does not guarantee that the NDA will be approved on an expedited basis or at all, and in February 2026 the FDA issued a CRL with respect to our NDA indicating that we would need to provide evidence of a clinical benefit from an additional clinical trial, such as our ongoing APOLLO trial, to support a potential approval." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm

### late 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-10-19, last confirmed 2026-10-19.
- SEC Form 8-K (accession 0001193125-26-424649): "Based on these results, the Company plans to resubmit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") by the end of 2026, with an FDA decision anticipated by mid-2027." https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263d8k.htm

### September 8, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06910358 (Study of Bitopertin in Participants With EPP or XLP (APOLLO)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-08 (ACTUAL); Lead Sponsor Disc Medicine, Inc." https://clinicaltrials.gov/study/NCT06910358

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP).
- First seen 2026-02-26, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-325031): "Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205187): "Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205187): ""We continue to make strong progress across the portfolio, completing enrollment in our Phase 3 trial of bitopertin in EPP and remaining on track to report top-line data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205187): "Completed enrollment of Phase 3 APOLLO clinical trial of bitopertin in adults and adolescents with EPP, with topline data expected Q4 2026; study size was expanded to 183 patients due to patient and physician demand" https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073594): "Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073594): "Progressing Phase 3 APOLLO clinical trial of bitopertin in adults and adolescents with EPP, with topline data expected Q4 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-ex99_1.htm
- ClinicalTrials.gov: "NCT06910358 (Study of Bitopertin in Participants With EPP or XLP (APOLLO)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-08 (ACTUAL); Lead Sponsor Disc Medicine, Inc." https://clinicaltrials.gov/study/NCT06910358

### October 19, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-02-26, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001193125-26-424649): "On October 19, 2026, the Company announced positive topline results from the APOLLO Phase 3 trial of bitopertin in EPP, including X-linked protoporphyria ("XLP")." https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263d8k.htm
- SEC prospectus (424B) (accession 0001193125-26-427982): "On October 19, 2026, we announced positive topline results from APOLLO Phase 3 trial of bitopertin in EPP, including XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526427982/d190758d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-425425): "On October 19, 2026, we announced positive topline results from APOLLO Phase 3 trial of bitopertin in EPP, including XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526425425/d190758d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "In October 2026, we announced positive topline results from APOLLO, a randomized, double-blind, pivotal Phase 3 trial evaluating the safety and efficacy of bitopertin versus placebo in adults and adolescents aged 12 or older with EPP or XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-450184): "In October 2026, we announced positive topline results from APOLLO, a randomized, double-blind, pivotal Phase 3 trial evaluating the safety and efficacy of bitopertin versus placebo in adults and adolescents aged 12 or older with EPP or XLP." https://www.sec.gov/Archives/edgar/data/1816736/000119312526450184/d187305d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "We completed enrollment in APOLLO (n=183) in the first quarter of 2026 and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "We completed enrollment in APOLLO (n=183) in the first quarter of 2026 and expect to report topline data in the fourth quarter of 2026, following which we plan to submit a response to the CRL and would then anticipate an FDA decision on our NDA by mid-2027." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073602): "We expect to report topline data from APOLLO in the fourth quarter of 2026, following which we plan to submit a response to the CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073602): "We plan to request a Type A meeting to review our approach with the FDA, and we expect to report topline data from APOLLO in the fourth quarter of 2026, following which we plan to submit a response to the CRL." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073602): "We plan to submit a response to the CRL following receipt of topline data from the APOLLO clinical trial, which we expect to report in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "We reported positive topline results from APOLLO in October 2026, and plan to engage with the FDA and resubmit an NDA by the end of 2026." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Erythropoietic Protoporphyria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05883748 (HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." https://clinicaltrials.gov/study/NCT05883748

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Erythropoietic Protoporphyria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05883748 (HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." https://clinicaltrials.gov/study/NCT05883748

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bitopertin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Bitopertin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bitopertin

```bibtex
@misc{secapidev_pdufa_bitopertin_20261116,
  title        = {Bitopertin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bitopertin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bitopertin_20261116","title":"Bitopertin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bitopertin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
